



29th Annual Cancer Progress Conference
May 8-9, 2018
Convene at 32 Old Slip, NYC

Tuesday, May 8, 2018

7:00 – 8:00am **Registration and Continental Breakfast**

8:00 – 8:15am **Opening Remarks**

Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health

8:15 – 9:15am **Keynote:**

Laura Esserman, MD, MBA, Director, UCSF Carol Franc Buck Breast Cancer Center; Professor of Surgery and Radiology, UCSF

9:15 – 10:30am **Cell Therapies as the New Space Race: Engineering Generation X.0**

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

Panelists: TBD

10:30 – 11:00am **Networking Break**

11:00 – 12:15pm **Oncology Diagnostics – Reading the Future**

Moderator: Joel Sandler, PhD, Associate Principal, Defined Health

Panelists:

- Ken Bloom, MD, President, Human Longevity
- Lisa H. Butterfield, PhD, Professor of Medicine, Surgery, Immunology and Clinical and Translational Science; Director, Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, UPMC Hillman Cancer Center
- Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString
- TBD

12:15 – 1:30pm **Networking Luncheon**

1:30 – 2:45pm **Progress in Intractable Cancers- Part I – Heme Malignancies**

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

Panelists:

- TBD

2:45 – 4:00pm **Innovative Trials & Collaborative Initiatives – Role of Patient Advocacy, Foundations & Institutes**

Moderator: TBD



Panelists:

- Lou DeGennaro, PhD, President and Chief Executive Officer, The Leukemia & Lymphoma Society
- Lorraine Egan, President and Chief Executive Officer, Damon Runyon
- Ramy Ibrahim, MD, Vice President, Clinical Research & Development, Parker Institute
- T.J. Sharpe, Patient Writer, Speaker, & Patient Experience Advisor, Starfish Harbor, LLC

4:00 – 4:15pm

Networking Break

4:15 – 5:30pm

Value & Pricing Redux – Does the Song Remain the Same?

Moderator: Ed Saltzman, Executive Chairman, Defined Health

Panelists:

- Daniel Becker, MD, MS, Section Chief, Hematology and Oncology, VA-NYHHS; Assistant Clinical Professor of Medicine, New York University School of Medicine
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Kapil Dhingra, MD, Managing Member, KAPital Consulting
- Roger Longman, Chief Executive Officer, Real Endpoints

5:30 – 7:30pm

Cancer Progress 2018 Reception

Wednesday, May 9, 2018

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks: Review of Day 1 (Mike Rice + TBD)

8:15 – 9:45 am

Advances in Intractable Cancers - Part II – Solid Tumors

Moderator: James Lee, PhD, Senior Consultant, Defined Health

Panelists:

- Patrick Tricoli, Chief Executive Officer & Vice President, Corporate Development, Nanobiotix
- David Tuveson, MD, PhD, Professor; Director of the Lustgarten Foundation Pancreatic Research Laboratory at CSHL; Director of Research for the Lustgarten Foundation
- Denise Reinke, MS, NP, MBA, President and Chief Executive Officer, SARC
- Wendy K.D. Selig, Founder and Chief Executive Officer, WSCollaborative, LLC

9:45 – 10:00am

Networking Break

10:00 – 11:15am

Innate & Adaptive Resistance to IO – Is It the TME's Time to Shine?

Moderator: Bruce Booth, DPhil, Partner, Atlas Ventures

Panelists:



- Tom Gajewski, MD, PhD, Professor, Department of Pathology, The Ben May Department for Cancer Research, Department of Medicine- Section of Hematology/Oncology, Chicago University
- Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
- TBD

11:15 – 12:30

Next Wave Antibodies and Biologics: Is IO Poised for a Sea of Change?

Moderator: Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health

Panelists:

- Mike Curran, PhD, Assistant Professor, The University of Texas, MD Anderson Cancer Center
- John Haurum, MD, DPhil, Chief Executive Officer, F-Star
- Carsten Reinhardt, MD, PhD, Chief Medical Officer, Immatics
- Taylor Schreiber, MD, PhD, Chief Scientific Officer, Shattuck Labs, Inc.

12:30 – 1:45pm

Networking Lunch

1:45 – 3:00 pm

Point-Counterpoint: Cancer Progress, at the Crossroads or at Tipping Point?

Moderator: Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health

Panelists:

- Christoph Lengauer, PhD, Executive Vice President, Blueprint Medicines
- Brian Leyland-Jones, MBBS, PhD, Vice President, Avera Cancer Institute Center for Precision Oncology and Department of Molecular and Experimental Medicine, Avera Cancer Institute
- Peter Sandor, MD, MBA, Vice President, Head of Oncology Therapeutic Area Marketing, Astellas Pharma US, Inc.
- TBD

3:15 pm

Cancer Progress 2018 Conference Concludes